Targeted Metallodrugs
2012
-
J. X. Ong, C. W. Yap, W. H. Ang*,
Rational Design of Selective Organoruthenium Inhibitors of Protein Tyrosine Phosphatase 1B,
Inorg. Chem.,
2012,
51,
12483-12492
-
A. Astarina, M. J. Chow, W. H. Ang*,
Transcription Inhibition by Organometallic Ruthenium–Arene Anticancer Complexes in Live Mammalian Cells,
Aust. J. Chem.,
2012,
65,
1271-1276
-
A. A. Nazarov, J. Risse, W. H. Ang, F. Schmitt, O. Zava, A. Ruggi, M. Groessl, R. Scopelitti, L. Juillerat-Jeanneret, C. G. Hartinger, P. J. Dyson,
Anthracene-Tethered Ruthenium(II) Arene Complexes as Tools To Visualize the Cellular Localization of Putative Organometallic Anticancer Compounds,
Inorg. Chem.,
2012,
51,
3633-3639
2011
-
Y. Q. Tan, P. J. Dyson, W. H. Ang*,
Acetal-Functionalized RAPTA Complexes for Conjugation and Labeling,
Organometallics,
2011,
30,
5965-5971
-
W. H. Ang, A. Casini, G. Sava, P. Dyson*,
Organometallic Ruthenium-Based Antitumor Compounds with Novel Modes of Action,
J. Organomet. Chem.,
2011,
696,
989-998
2009
-
W. H. Ang, L. J. Parker, A. De Luca, L. Juillerat-Jeanneret, C. J. Morton, M. Lo Bello, M. W. Parker, Paul J. Dyson*,
Rational Design of an Organometallic Glutathione Transferase Inhibitor,
Angew. Chem. Int. Ed. Engl.,
2009,
48,
3854-3857
-
W. H. Ang, Z. Grote, R. Scopelliti, L. Juillerat-Jeanneret, K. Severin, P. J. Dyson*,
Organometallic complexes that interconvert between trimeric and monomeric structures as a function of pH and their effect on human cancer and fibroblast cells,
J. Organomet. Chem.,
2009,
694,
968-972
2008
-
A. Mathieu, B. Therrien, G. Süss-Fink, P. Stepnicka, W. H. Ang, P. J. Dyson*,
Ferrocenoyl Pyridine Arene Ruthenium Complexes with Anticancer Properties: Synthesis, Structure, Electrochemistry, and Cytotoxicity,
Inorg. Chem.,
2008,
47,
578-583
-
F. Schmitt, P. Govindaswamy, G. Süss-Fink, W. H. Ang, P. J. Dyson, L. Juillerat-Jeanneret*, B. Therrien*,
Ruthenium-porphyrin compounds for photodynamic therapy of cancer,
J. Med. Chem.,
2008,
51,
1811-1816
2007
-
C. A. Vock, W. H. Ang, C. Scolaro, L. Juillerat-Jeanneret*, G. Sava, P. J. Dyson*,
Synthesis, characterisation and in vitro evaluation of novel ruthenium(II) η6-arene complexes with MDR modulators as ligands,
J. Med. Chem.,
2007,
50,
2166 -2175
-
W. H. Ang*, A. De Luca, C. Chapuis-Bernasconi, L. Juillerat-Jeanneret, M. Lo Bello*,
Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs,
ChemMedChem,
2007,
2,
1799-1806
-
B. Therrien, W. H. Ang, F. Chérioux, L. Vieille-Petit, L. Juillerat-Jeanneret, G. Süss-Fink*, P. J. Dyson*,
Remarkable anticancer activity of triruthenium-arene clusters compared to tetraruthenium-arene clusters,
J. Cluster Sci.,
2007,
18,
741-752
-
A. Casini, G. Mastrobuoni, W. H. Ang, C. Gabbiani, G. Pieraccini, G. Moneti, P. J. Dyson*, L. Messori*,
ESI-MS characterization of protein adducts of anticancer ruthenium(II)-arene PTA (RAPTA) complexes,
ChemMedChem,
2007,
2,
631-635
-
W. H. Ang, E. Daldini, L. Juillerat-Jeanneret, P. J. Dyson*,
Strategy to tether organometallic ruthenium-arene anti-cancer compounds to recombinant human serum albumin,
Inorg. Chem.,
2007,
46,
9048-9050
-
W. H. Ang*,
Development of organometallic ruthenium(II) anticancer (RAPTA) drugs -Invited Paper-,
Chimia,
2007,
61,
140-142
2006
-
W. H. Ang, P. J. Dyson*,
Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy,
Eur. J. Inorg. Chem.,
2006,
20,
4003-4018
-
A. Dorcier, W. H. Ang, S. Bolaño, L. Gonsalvi, L. Juillerat-Jeannerat, G. Laurenczy, M. Peruzzini, A. D. Phillips, F. Zanobini, P. J. Dyson*,
In vitro evaluation of rhodium and osmium RAPTA analogues: the case for organometallic anticancer drugs not based on ruthenium,
Organometallics,
2006,
25,
4090-4096
-
W. H. Ang, E. Daldini, C. Scolaro, R. Scopelliti, L. Juillerat-Jeanneret, P. J. Dyson*,
Development of ruthenium arene anticancer drugs that resist hydrolysis,
Inorg. Chem.,
2006,
45,
9006-9013
